Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

William Butron

Internal Medicine Tulsa, OK Medical Doctor

NPI 1467743443 CMS profile 1325169

591 E 36Th St N, Tulsa, OK 74106

Open in the dashboard

General payments

$5,456

318 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Butron of Tulsa, OK is reported in the CMS Open Payments database as having received $5,456 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,041 118
2024 General $1,893 109
2023 General $1,342 81
2022 General $180 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Butron
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Butron were reported at $2,041. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Butron Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $180 $141 $42–$496 $149
2023 $1,342 $149 $45–$519 $160
2024 $1,893 $154 $47–$537 $164
2025 $2,041 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,085 47 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $612 37 payments
  3. AbbVie, Inc. $491 44 payments
  4. Lilly USA, LLC $466 27 payments
  5. Pfizer Inc. $406 22 payments
  6. Novo Nordisk Inc $380 22 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $358 25 payments
  8. Astellas Pharma US Inc $252 11 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $206 12 payments
  10. Aimmune Therapeutics, Inc. $194 10 payments
  11. Other $1,007 61 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,456 318 payments
Products named General payments · program years 2022–2025
  1. Kerendia $612 37 payments
  2. FARXIGA $544 16 payments
  3. BREZTRI $540 21 payments
  4. AIRSUPRA $454 14 payments
  5. MOUNJARO $448 26 payments
  6. NURTEC ODT $386 21 payments
  7. ZAVZPRET $337 18 payments
  8. JARDIANCE $306 22 payments
  9. Veozah $252 11 payments
  10. ZEPBOUND $234 14 payments
  11. Other $2,947 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 164 drugs

Part D claims

10,364

Median for Internal Medicine: 777

Drug cost

$1,518,245

Median for Internal Medicine: $73,373

Branded share of claims

25.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trikafta Elexacaftor/Tezacaftor/Ivacaft Brand 13 $339,258
Jardiance Empagliflozin Brand 183 $162,983
Eliquis Apixaban Brand 100 $99,499
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 114 $92,206
Farxiga Dapagliflozin Propanediol Brand 89 $91,087
Creon Lipase/Protease/Amylase Brand 26 $86,847
Ozempic Semaglutide Brand 76 $83,808
Rybelsus Semaglutide Brand 43 $68,750
Mounjaro Tirzepatide Brand 46 $67,512
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 55 $41,039

The 10 drugs with the highest cost, of 164 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$75,884

Of which drugs: $6,539

Medicare patients

195

Average age 72

Services billed

6,695

79 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Depression 29%
Diabetes 28%
Ischemic heart disease 23%
Heart failure 21%
Chronic kidney disease 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 47 47 $3,764
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 64 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $197
$197 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $184
$184 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $184
$184 55 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $172
$172 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $172
$172 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record